If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
Logan Lutton
Advertisement
Logan Lutton is a contributing author for Medical Economics.
Articles by Logan Lutton
An alarming amount of COVID-19 disinformation is prevalent even from physicians.
An expected rise in COVID-19 cases in combination with other preventable diseases could overwhelm the healthcare system.
A new survey identifies what executives think could be the biggest disruptions in the next year for hospitals and health care groups.
Advertisement
Latest Updated Articles
How Will COVID-19 Disrupt Healthcare Going Forward?Published: March 18th 2021 | Updated:
ACP Encourages Americans to Get Vaccinated Against Preventable Diseases – Not Just COVID-19Published: August 23rd 2021 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
